Fundraising Fox
/Companies
Sign in

Sutrobio

NASDAQ: STRO

South San Francisco, US · Founded 2003 · 6 known investors

Find your way into Sutrobio

Sign up to see every warm intro you have to Sutrobio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Sutrobio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

WJ
William J. NewellExecutive
JCJane Chung
Jane ChungChief Executive OfficerCEO of Sutrobio, a biotech company developing cell-free protein synthesis technology for the manufacture of complex biologics including cancer therapies and antibody-drug conjugates.
HGHans-Peter Gerber
Hans-Peter GerberChief Scientific OfficerHans-Peter Gerber spent over 25 years in biotech and pharmaceutical R&D, with expertise in oncology and immuno-oncology drug development, including therapeutic antibodies, antibody-drug conjugates, and bispecific molecules. He previously held leadership roles at Pfizer in oncology research and contributed to regulatory submissions for multiple cancer therapeutics, including Avastin and Inotuzumab Ozogamicin, and holds over 100 publications and 20 patents.
DPDavid Pauling
David PaulingChief Administrative Officer and General CounselChief Administrative Officer and General Counsel at Sutrobio, David Pauling has experience in biopharma leadership with focus on corporate strategy, risk management, and governance.
JFJonathan Fawcett
Jonathan FawcettVP, Head of Clinical DevelopmentJonathan Fawcett is a surgeon with training in hepatobiliary and transplant medicine, including a PhD from the University of Oxford's Institute of Molecular Medicine and academic appointments at Oxford and the University of Queensland, where he held a professorship and directed the liver transplant service.
DL
Devendra LuharSVP, Technical OperationsDevendra Luhar holds extensive experience in biotechnology manufacturing operations, including antibody manufacturing, warehouse and logistics management, and engineering. His background spans both mammalian and microbial cell culture and purification, with hands-on experience managing multiproduct manufacturing for internal and contract manufacturing organizations, with demonstrated expertise in lean manufacturing and process improvement methodologies.
JL
Joseph LobackiNamed on SEC filing
VB
Virgil Bryan LawlisNamed on SEC filing
MR
Michael RossNamed on SEC filing
DP
Daniel PetreeNamed on SEC filing

Board

DJ
Daniel JanneyBoard director
AS
Armen ShanafeltBoard director

Investors · 6

Ridgeback Capitallisted by Ridgeback CapitalNew York

How we know: Ridgeback Capital's portfolio page · Not right? Tell us

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

Solasta Ventureslisted by Solasta VenturesBoston
SV Health InvestorsreportedLondon · $1M – $20M

How we know: the S-1 prospectus · Not right? Tell us

Vida VenturesreportedLos Angeles

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$85.4M disclosed across 1 round · 2018

▶$85.4MraisedAug 2018 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph LobackiDirector
  • Daniel JanneyDirector
  • Armen ShanafeltDirector
  • Virgil Bryan LawlisDirector
  • John G. FreundDirector
  • William J. NewellExecutive Officer, Director
  • Michael DybbsDirector
  • Michael RossDirector
  • Daniel PetreeDirector
Offering amount
$85.4M
Amount sold
$85.4M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$342.4Mvaluation at IPOSep 2018 · $15.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

3 people who came through Sutrobio went on to found or lead other companies.

Mike DybbsDirectorFounded Kalaris Therapeutics, Inc.Christopher ThanosDirector, Protein EngineeringFounded XDemicsHans-Peter GerberChief Scientific OfficerFounded 3T Biosciences

Frequently asked questions

What does Sutrobio do?
Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.
Who are Sutrobio's investors?
Sutrobio's investors include Owl Capital, Ridgeback Capital, Samsara BioCapital, Solasta Ventures, SV Health Investors, Vida Ventures.
How much funding has Sutrobio raised?
Sutrobio has disclosed $85.4M raised across 1 round.
Where is Sutrobio headquartered?
Sutrobio is headquartered in South San Francisco, US.